Profile of Exon 20 T790M Mutation Incidence Rate with Plasma ctDNA in Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment
Downloads
Introduction: Patients with lung adenocarcinoma following epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment will develop acquired resistance after 7 to 16 months of starting the medication, indicated by the emergence of exon 20 T790M mutations. This study aimed to identify the clinical and demographical profile of acquired resistance in patients with lung adenocarcinoma receiving EGFR-TKI therapy through plasma circulating tumor deoxyribonucleic acid (ctDNA) examination.
Methods: This was a descriptive study with a retrospective cross-sectional design involving 108 lung adenocarcinoma patients who received EGFR-TKI for more than six months. Exon 20 T790M EGFR mutations were identified as a sign of acquired resistance using the digital droplet polymerase chain reaction (ddPCR) approach to examine plasma ctDNA Utilizing the Statistical Package for the Social Sciences, statistical tests were used to examine the data (SPSS). The data were analyzed by statistical tests using the Statistical Package for the Social Sciences (SPSS).
Results: A total of 31 patients were recruited as study participants. The majority of the research subjects were female (64.5%), aged 20-69 years old (58%), and non-smokers (67.7%). Exon 19 deletions were the most prevalent EGFR mutation (58.1%). The incidence of acquired resistance was found in 10 subjects (32.3%). Patients with acquired resistance were predominately female (70%), non-smokers (80%), and with gefitinib therapy (90%). The average time for EGFR-TKI treatment until acquired resistance occurred was 12.6 months.
Conclusion: The incidence of acquired resistance was mainly found in women without a smoking history after 12.6 months of treatment with EGFR-TKI.
Soeroso NN, Tanjung MF, Afiani D, et al. Procalcitonin Level in Non-Small Cell Lung Cancer Patients among Indonesian Population. Open Access Maced J Med Sci 2018; 6: 2123–2127. [PubMed]
KPKN. Pedoman Nasional Pelayanan Kedokteran Kanker Paru. Jakarta: Kementerian Kesehatan Republik Indonesia, 2017.
Murtaza M, Dawson SJ, Tsui DWY, et al. Non-Invasive Analysis of Acquired Resistance to Cancer Therapy by Sequencing of Plasma DNA. Nature 2013; 497: 108–112.[PubMed]
Fenizia F, Luca AD, Pasquale R, et al. EGFR Mutations in Lung Cancer: From Tissue Testing to Liquid Biopsy. Futur Oncol 2015; 11: 1611–1623. [PubMed]
Bettegowda C, Sausen M, Leary RJ, et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Sci Transl Med 2014; 6: 224ra24. [PubMed]
Elhidsi M, Andarini SL, Hudoyo A. Profil Mutasi Epidermal Growth Factor Receptor Pasien Adenokarsinoma Paru Usia Muda. J Respirologi Indones 2016; 36: 244–248. [Journal]
Subramanian J, Morgensztern D, Goodgame B, et al. Distinctive Characteristics of Non-Small Cell Lung Cancer (NSCLC) in the Young: A Surveillance, Epidemiology, and End Results (SEER) Analysis. J Thorac Oncol 2010; 5: 23–28. [PubMed]
Brenner DR, Hung RJ, Tsao MS, et al. Lung Cancer Risk in Never-Smokers: A Population-Based Case-Control Study of Epidemiologic Risk Factors. BMC Cancer 2010; 10: 285. [PubMed]
Shi P, Oh YT, Zhang G, et al. Met Gene Amplification and Protein Hyperactivation is a Mechanism of Resistance to Both First and Third Generation EGFR Inhibitors in Lung Cancer Treatment. Cancer Lett 2016; 380: 494–504. [PubMed]
Mohan A, Garg A, Gupta A, et al. Clinical Profile of Lung Cancer in North India: A 10-Year Analysis of 1862 Patients from a Tertiary Care Center. Lung India 2020; 37: 190–197. [PubMed]
Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or Carboplatin Paclitaxel in Pulmonary Adenocarsinoma. N Engl J Med 2009; 361: 947–957. [PubMed]
Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors. Sci Transl Med 2011; 3: 75ra26. [PubMed]
Parkin DM, Bray F, Ferlay J, et al. Global Cancer Statistics 2002. CA Cancer J Clin 2005; 55: 74–108. [PubMed]
Syahruddin E, Wulandari L, Muktiati NS, et al. Uncommon EGFR Mutations in Cytological
Specimens of 1,874 Newly Diagnosed Indonesian Lung Cancer Patients. Lung Cancer 2018; 9: 25–34. [PubMed]
Nagano T, Tachihara M, Nishimura Y. Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy. Cells 2018; 7: 212. [PubMed]
Ettinger DS, Wood DE, Aggarwal C, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer. J Natl Compr Canc Netw 2019; 17: 1464–1472. [PubMed]
Yun CH, Mengwasser KE, Toms AV, et al. The T790M Mutation in EGFR Kinase Causes Drug Resistance by Increasing the Affinity for ATP. Proc Natl Acad Sci USA 2008; 105: 2070–2075. [PubMed]
Wee P, Wang Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers (Basel) 2017; 17. [PubMed]
Huang L, Fu L. Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors. Acta Pharm Sin B 2015; 5: 390–401. [PubMed]
Ciardiello F, Tortora G. EGFR Antagonists in Cancer Treatment. N Engl J Med 2008; 358: 1160–1174. [PubMed]
Copyright (c) 2023 Muhammad Harbi Praditya, Noni Novisari Soeroso, Setia Putra Tarigan, Taufik Ashar, Darren Wan-Teck Lim
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (